Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010404 | 0.85 | ALDH1A1 (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL6010265 | 0.81 | KDM4E (0.35) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL27906144 | 0.77 | ALDH1A1 (0.36) | PDCD1LG2CD274MMETP53 | |
| SCHEMBL6010366 | 0.76 | ALDH1A1 (0.44) | MEN1KMT2ALMNAMME | |
| SCHEMBL6009834 | 0.76 | TGFBR1 (0.40) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL19091217 | 0.74 | LMNA (0.36) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL9405945 | 0.74 | LMNA (0.36) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL25706379 | 0.74 | LMNA (0.36) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL6010220 | 0.72 | PDCD1LG2 (0.35) | PDCD1LG2CD274OR51E2MMEVSIR | |
| SCHEMBL6010210 | 0.72 | PDCD1LG2 (0.35) | PDCD1LG2CD274OR51E2MMEVSIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | KDM4E 3805/4885DUSP3 397/4885MEN1 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.